CYP2D6 Allelic Variants *34, *17-2, *17-3, and *53 and a Thr309Ala Mutant Display Altered Kinetics and NADPH Coupling in Metabolism of Bufuralol and Dextromethorphan and Altered Susceptibility to Inactivation by SCH 66712-Reference-Cited by-同舟云学术

CYP2D6 Allelic Variants *34, *17-2, *17-3, and *53 and a Thr309Ala Mutant Display Altered Kinetics and NADPH Coupling in Metabolism of Bufuralol and Dextromethorphan and Altered Susceptibility to Inactivation by SCH 66712

Published:2018-05-21 Issue:8 Volume:46 Page:1106-1117
ISSN:0090-9556
Container-title:Drug Metabolism and Disposition
language:en
Short-container-title:Drug Metab Dispos

Author:

Glass Sarah M.,Martell Cydney M.,Oswalt Alexandria K.,Osorio-Vasquez Victoria,Cho Christi,Hicks Michael J.,Mills Jacqueline M.,Fujiwara Rina,Glista Michael J.,Kamath Sharat S.,Furge Laura Lowe

Publisher

American Society for Pharmacology & Experimental Therapeutics (ASPET)

Subject

Pharmaceutical Science,Pharmacology

Reference54 articles.

1. Sulfenylation of Human Liver and Kidney Microsomal Cytochromes P450 and Other Drug-Metabolizing Enzymes as a Response to Redox Alteration

2. Mechanism-Based Inactivation of Human Cytochrome P450 3A4 by Two Piperazine-Containing Compounds

3. Binding of bufuralol, dextromethorphan, and 3,4-methylenedioxymethylamphetamine to wild-type and F120A mutant cytochrome P450 2D6 studied by resonance Raman spectroscopy;Bonifacio;Biochem Biophys Res Commun,2006

4. Chicago (2016) The 1200 Patients Project. https://cpt.uchicago.edu/page/1200-patients-project

5. Adverse Drug Events in Hospitalized PatientsExcess Length of Stay, Extra Costs, and Attributable Mortality

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Identification of Novel CYP2D6 Variants in US Hmong: Results From Genome Sequencing and Clinical Genotyping;Frontiers in Pharmacology;2022-03-21

2. Tryptophan-75 Is a Low-Energy Channel-Gating Residue that Facilitates Substrate Egress/Access in Cytochrome P450 2D6;Drug Metabolism and Disposition;2020-12-29

3. Spontaneous Ligand Access Events to Membrane-Bound Cytochrome P450 2D6 Sampled at Atomic Resolution;Scientific Reports;2019-11-11

4. Rolapitant Is a Reversible Inhibitor of CYP2D6;Drug Metabolism and Disposition;2019-04-05